Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep;261(6):433-46.
doi: 10.1007/s00406-010-0184-0. Epub 2011 Jan 5.

A visual [18F]FDG-PET rating scale for the differential diagnosis of frontotemporal lobar degeneration

Affiliations

A visual [18F]FDG-PET rating scale for the differential diagnosis of frontotemporal lobar degeneration

Stefan Poljansky et al. Eur Arch Psychiatry Clin Neurosci. 2011 Sep.

Abstract

This study presents a visual rating scale for the assessment of cerebral [(18)F]fluoro-2-deoxy-D: -glucose positron emission tomography (FDG-PET) scans to characterize typical findings in dementias associated with frontotemporal lobar degeneration (FTLD) and to differentiate individual patients with FTLD compared to Alzheimer's disease (AD) and mild cognitive impairment (MCI). A total of 43 cerebral PET scans from patients with FTLD (n = 16, mean age 58.4 years), AD (n = 16, 59.9 years) and MCI (n = 11, 57.9 years) were analysed. Every PET data set was visually rated for seven brain regions on each hemisphere (frontal lobe, temporal lobe, parietal lobe, occipital lobe, basal ganglia, thalamus and cerebellum). The extent of the impairment in metabolism was classified as absent, mild, medium or strong. Using this four-stage visual rating scale, characteristic profiles of metabolic impairment in FTLD, AD, MCI and the FTLD-subgroup FTD (n = 9) could be demonstrated. Patients with FTLD showed a significantly lower metabolism in the left frontal lobe and in the left basal ganglia when compared to AD and to MCI. Complementary analyses using statistical parametric mapping (SPM2) supported the findings of the visual analysis. In detecting FTLD with visual rating, sensitivity/specificity was 81/94% compared to AD and 81/64% compared to MCI. Patients with FTD were correctly attributed to a diagnosis of FTLD with a sensitivity of 89%. This visual rating scale may facilitate the differential diagnosis of FTLD in clinical routine.

PubMed Disclaimer

Similar articles

  • Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors.
    Womack KB, Diaz-Arrastia R, Aizenstein HJ, Arnold SE, Barbas NR, Boeve BF, Clark CM, DeCarli CS, Jagust WJ, Leverenz JB, Peskind ER, Turner RS, Zamrini EY, Heidebrink JL, Burke JR, DeKosky ST, Farlow MR, Gabel MJ, Higdon R, Kawas CH, Koeppe RA, Lipton AM, Foster NL. Womack KB, et al. Arch Neurol. 2011 Mar;68(3):329-37. doi: 10.1001/archneurol.2010.295. Epub 2010 Nov 8. Arch Neurol. 2011. PMID: 21059987 Free PMC article.
  • 18F-FDG PET for the differential diagnosis of Alzheimer's disease and frontotemporal lobar degeneration: A multicenter prospective study in Japan.
    Ito K, Washimi Y, Kato T, Suzuki K, Ouchi Y, Watanabe C, Sunada Y, Kutoku Y, Ishii K, Ishii K, Kitayama M, Matsubara E, Kimura N, Takano H, Adachi H, Hara K, Kawarabayashi T, Shoji M, Sugimoto N; SDAF-PET Study Group. Ito K, et al. J Alzheimers Dis. 2025 Jul;106(1):293-303. doi: 10.1177/13872877251338691. Epub 2025 May 5. J Alzheimers Dis. 2025. PMID: 40325872 Free PMC article.
  • Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD.
    Rabinovici GD, Rosen HJ, Alkalay A, Kornak J, Furst AJ, Agarwal N, Mormino EC, O'Neil JP, Janabi M, Karydas A, Growdon ME, Jang JY, Huang EJ, Dearmond SJ, Trojanowski JQ, Grinberg LT, Gorno-Tempini ML, Seeley WW, Miller BL, Jagust WJ. Rabinovici GD, et al. Neurology. 2011 Dec 6;77(23):2034-42. doi: 10.1212/WNL.0b013e31823b9c5e. Epub 2011 Nov 30. Neurology. 2011. PMID: 22131541 Free PMC article.
  • Clinical utility of FDG-PET for the clinical diagnosis in MCI.
    Arbizu J, Festari C, Altomare D, Walker Z, Bouwman F, Rivolta J, Orini S, Barthel H, Agosta F, Drzezga A, Nestor P, Boccardi M, Frisoni GB, Nobili F; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Arbizu J, et al. Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1497-1508. doi: 10.1007/s00259-018-4039-7. Epub 2018 Apr 27. Eur J Nucl Med Mol Imaging. 2018. PMID: 29704037 Review.
  • Brain fluorodeoxyglucose (FDG) PET in dementia.
    Kato T, Inui Y, Nakamura A, Ito K. Kato T, et al. Ageing Res Rev. 2016 Sep;30:73-84. doi: 10.1016/j.arr.2016.02.003. Epub 2016 Feb 11. Ageing Res Rev. 2016. PMID: 26876244 Review.

Cited by

References

    1. Radiology. 1996 Mar;198(3):837-43 - PubMed
    1. Brain. 2007 Oct;130(Pt 10):2616-35 - PubMed
    1. J Cereb Blood Flow Metab. 1991 Jul;11(4):690-9 - PubMed
    1. Psychol Med. 1991 Feb;21(1):225-36 - PubMed
    1. Eur Arch Psychiatry Clin Neurosci. 2009 Jun;259(4):227-33 - PubMed

MeSH terms

Substances

LinkOut - more resources